Jacobs Levy Equity Management, Inc Caladrius Biosciences, Inc. Transaction History

Jacobs Levy Equity Management, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$4.85 - $6.5 $169,148 - $226,694	-34,876 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$3.8 - $8.64 $5,722 - $13,011	-1,506 Reduced 4.14%	34,876 $226,000
Q1 2018 May 15, 2018	SELL	$3.7 - $6.09 $4,810 - $7,917	-1,300 Reduced 3.45%	36,382 $212,000
Q3 2017 Nov 14, 2017	BUY	$3.58 - $4.34 $52,951 - $64,192	14,791 Added 64.61%	37,682 $135,000
Q2 2017 Nov 09, 2017	BUY	N/A	22,891	22,891 $106,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.